Fadi Atassi, MD
Interventional Cardiology · Lake Havasu City, AZNPI 1851553119
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,680 of the $60,145 with a category attached, or 62.6%. Johnson & Johnson accounts for 66.9% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2022 at $16,283 and has fallen 78.0% since, to $3,579 in 2025.
Across 659 payments — averaging $91.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$40K
- Abbott$3K
- Cvrx, Inc.$2K
- Abiomed$2K
- Novartis$2K
- Medtronic$1K
- plus $9K from 39 others
What the payments were for
- Consulting fees$3151%
- Speaking & faculty fees$37,68063%
- Travel & lodging$8401%
- Food & beverage$21,28935%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$38,927
- Barostim Neo System$1,698
- Impella$929
- CARDIOMEMS$651
- GORE VIABAHN VBX Balloon Expandable Endo$297
- XIENCE SIERRA$282
- EMBOSHIELD NAV6$261
- Fortify Assura, Ellipse ICD$252
- UPTRAVI$248
- VERQUVO$248
- Carto 3$237
- ENTRESTO$237
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$236
- Inspire Upper Airway Stimulation System$230
- Auryon Laser System 100-120 Vac$221
- GENERAL ULTRASOUND$174
- Ovation$146
- AFX$146
- ECM Patch,Pouch$137
- Micra$125
How this compares
$60,145 in reported general payments places this provider in the 85th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,156 | $1,543,265 |
| XareltoRivaroxaban | 637 | $869,192 |
| OpsumitMacitentan | 39 | $507,536 |
| EntrestoSacubitril/Valsartan | 297 | $423,308 |
| UptraviSelexipag | 12 | $298,227 |
| AdempasRiociguat | 12 | $178,291 |
| Repatha SureclickEvolocumab | 98 | $118,353 |
| BrilintaTicagrelor | 124 | $94,423 |
| FarxigaDapagliflozin Propanediol | 27 | $39,730 |
| MultaqDronedarone Hcl | 11 | $25,572 |
| Metoprolol Succinate | 1,237 | $17,329 |
| Atorvastatin Calcium | 1,398 | $13,712 |
| JardianceEmpagliflozin | 11 | $10,756 |
| Rosuvastatin Calcium | 560 | $9,204 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 27 | $8,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $237 | $1,543,2651,156 claims |
| Johnson & JohnsonXarelto | $40,254 | $869,192637 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $778 | $805,76351 claims |
| NovartisEntresto | $1,597 | $423,308297 claims |
| AstraZenecaBrilinta, Farxiga | $92 | $134,153151 claims |
| Sanofi-aventis U.S. LLCMultaq | $21 | $25,57211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Lake Havasu City
- Rafael Francisco GoLake Havasu City$30K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Kapildeo LotunTucson$365K
- Azimuddin KhawajaPeoria$199K
- Rahul SharmaPeoria$195K
- Taral PatelScottsdale$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.